Zobrazeno 1 - 5
of 5
pro vyhledávání: '"M. Alexandra Schickli"'
Autor:
Robert Wesolowski, Junan Li, Raquel E. Reinbolt, Bhuvaneswari Ramaswamy, Jonathan Wilkie, Craig A. Vargo, Sagar Sardesai, Anne M. Noonan, Michael Berger, M. Alexandra Schickli, Nicole Williams, Maryam B. Lustberg, Daniel G. Stover, Jeffrey VanDeusen
Publikováno v:
Clinical Breast Cancer. 20:33-40
Background Additional use of cyclin-dependent kinase 4/6 inhibitors with endocrine therapy improves progression-free survival (PFS) in advanced hormone receptor (HR)-positive HER2-negative breast cancer. However, neutropenia is a common reason for do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a88dbe4a5181cc857b6e5be6a5a0ca5
https://doi.org/10.1016/j.clbc.2019.06.010
https://doi.org/10.1016/j.clbc.2019.06.010
Autor:
M Alexandra Schickli, Eric McLaughlin, Vinay K. Puduvalli, Tracelyn Freeman, Carlo S. Legasto, Pierre Giglio, Javier Gonzalez
Publikováno v:
Neurooncol Adv
Background Primary central nervous system lymphoma (PCNSL) is a rare malignancy with few treatment options. One regimen used for induction is rituximab, high-dose methotrexate (HD-MTX), procarbazine, and vincristine (R-MPV). A common institutional pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c6c41db17681660d69a06726f1e5c41
https://europepmc.org/articles/PMC7372924/
https://europepmc.org/articles/PMC7372924/
Publikováno v:
Annals of Pharmacotherapy. 51:27-32
Background: Dexmedetomidine is a widely utilized agent in the intensive care unit (ICU) because it does not suppress respiratory drive and may be associated with less delirium than midazolam or propofol. Cost of dexmedetomidine therapy and debate as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d106e060d0a5bbed06b3738735fa722
https://doi.org/10.1177/1060028016666100
https://doi.org/10.1177/1060028016666100
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 25(6)
Purpose The management of endocrine therapy resistance is one of the most challenging facets of advanced breast cancer treatment. Palbociclib is an inhibitor of cyclin-dependent kinases 4 and 6 approved for the treatment of hormone receptor-positive,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64294e5807e9d4cf08797bb211ea0464
https://pubmed.ncbi.nlm.nih.gov/30134767
https://pubmed.ncbi.nlm.nih.gov/30134767
Autor:
Susan K. Buchanan, Grzegorz Piszczek, Pallab Pahari, Jürgen Rohr, Madan K. Kharel, Nicholas Noinaj, Mary A. Bosserman, M. Alexandra Schickli
GilR is a recently identified oxidoreductase that catalyzes the terminal step of gilvocarcin V biosynthesis and is a unique enzyme that establishes the lactone core of the polyketide-derived gilvocarcin chromophore. Gilvocarcin-type compounds form a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfe01593c779bb2820fde3052c8e8e0a
https://europepmc.org/articles/PMC3123116/
https://europepmc.org/articles/PMC3123116/